Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Join an expert panel for a webinar on Smart investments for a secure retirement January 28, 2021. Register now!
you are here: HomeNewsBusiness

Covaxin vs Covishield: Bharat Biotech, Serum Institute CEOs take a jab at each other, here is what they said

Bharat Biotech Chairman Krishna Ella apparently hit back at Serum Institute of India chief Adar Poonawalla’s jibe calling vaccines other than those by AstraZeneca, Moderna and Pfizer as 'like water'.

January 05, 2021 / 02:09 PM IST

Bharat Biotech Chairman Krishna Ella has hit back at doubters saying the company is receiving unfounded backlash as it has done “200 percent honest clinical trials” for Covaxin, its candidate vaccine against COVID-19.

Speaking to reporters on January 4, Ella seemingly also took a back-swipe at Serum Institute of India (SII) chief Adar Poonawalla’s jibe calling vaccines other than those by AstraZeneca, Moderna and Pfizer as “like water.”

Follow our LIVE Updates on the coronavirus pandemic here

"We do 200 percent honest clinical trials and yet we receive backlash. If I am wrong, tell me. Some companies have branded me like water," he said. “Bharat Biotech was the first to identify the Zika virus and the first to file global patents for the Zika and Chikungunya vaccines,” Ella said while emphasising their coronavirus vaccine was “not inferior to the one developed by Pfizer.”

Bharat Biotech has faced a barrage of questions and concerns after the Drugs Controller General of India (DCGI) announced the grant of emergency use authorisation for its Covaxin and AstraZeneca-Oxford University’s vaccine candidate Covishield. SII is producing AstraZeneca's vaccine in India as Covishield.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Check here for the latest updates on all COVID-19 vaccines

Ella deflected criticism from industry experts and opposition leaders, asserting that the company has “a track record of producing safe and efficacious vaccines and has been transparent with all data.” He also said that Phase III data for Covaxin trials will be available in March.

He further said that sufficient data has already been revealed and is available online for people to access and suggested that Covaxin is being targeted and called “inferior” with questions raised about “sidestepping processes” and “premature clearances” because it is “a product of an Indian company.”

Follow our full COVID-19 coverage here
Moneycontrol News
first published: Jan 5, 2021 12:36 pm
Sections